UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC...
Larotrectinib New Drug Application (NDA) PDUFA date is November 26, 2018 LOXO-292 Registrational Data...
STAMFORD, Conn., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical...
STAMFORD, Conn., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical...
Larotrectinib Delivers 81% Overall Response Rate in an Expanded Dataset of 109 TRK Fusion Cancer Patients...
STAMFORD, Conn., Oct. 15, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical...
STAMFORD, Conn., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical...
- 16/17 (94%) Responding RET-Mutant Medullary Thyroid Cancer Patients Remain on Therapy, With Median Follow-Up...
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may...
Personalized Immunotherapy Could Be the Future for Advanced Breast Cancer TreatmentNetworkNewsWire Editorial Coverage: Personalized treatment for...
- 25/26 (96%) Responding Patients Remain on Therapy, With Median Follow-Up of 9.5 Months - STAMFORD, Conn...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.